Edit Entry | Edit CV

Todd W Miller, PhD

Adjunct Professor of Molecular and Systems Biology

Additional Titles/Positions/Affiliations
Co-Director, Cancer Signaling, Genomes & Networks Research Program, Dartmouth Cancer Center
Scientific Director, Comprehensive Breast Program, Dartmouth Cancer Center
Co-Director, Molecular Tumor Board, Dartmouth Cancer Center

Molecular and Systems Biology

University of Connecticut (Storrs, CT), B.S., Physiology & Neurobiology, 1998
University at Albany (Albany, NY), Ph.D. in Biomedical Sciences, 2004
Vanderbilt University (Nashville, TN), Post-doctoral Fellowship in Breast Cancer, 2004-2009

Molecular and Cellular Biology Graduate Programs
Norris Cotton Cancer Center

Websites Lab website:



Academic Analytics
View Profile

Contact Information

1 Medical Center Drive
Rubin Bldg, HB 7936
Lebanon NH 03756

Office: Rubin 604
Phone: 603-646-5507
Email: Todd.W.Miller@Dartmouth.edu

Professional Interests

Breast cancer, targeted therapeutics, signaling pathways, drug resistance, biomarker development


Dr. Miller received his B.S. in Physiology and Neurobiology at the University of Connecticut in 1998, and his Ph.D. in Biomedical Sciences at the State University of New York at Albany in 2004 (thesis: Immunization and single-chain Fv intrabody gene therapies for Huntington’s Disease). He did his postdoctoral training at Vanderbilt University (2004-2009), and served as a Research Faculty member 2009-2012. Dr. Miller joined the Geisel School of Medicine at Dartmouth in 2012.

Selected Publications


Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer.
Traphagen NA, Schwartz GN, Tau S, Roberts AM, Jiang A, Hosford SR, Marotti JD, Goen AE, Romo BA, Johnson AL, Duffy EK, Demidenko E, Heverly P, Mosesson Y, Soucy SM, Kolling F, Miller TW
Clin Cancer Res. 2023 Sep 15;29(18):3717-3728. doi: 10.1158/1078-0432.CCR-23-0488.
PMID: 37439680

Alteration of DNMT1/DNMT3A by eribulin elicits global DNA methylation changes with potential therapeutic implications for triple-negative breast cancer.
Bagheri M, Lee MK, Muller KE, Miller TW, Pattabiraman DR, Christensen BC
bioRxiv. 2023 Jun 10; pii: 2023.06.09.544426. doi: 10.1101/2023.06.09.544426. Epub 2023 Jun 10.
PMID: 37333096

Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer.
Schwartz GN, Kaufman PA, Giridhar KV, Marotti JD, Chamberlin MD, Arrick BA, Makari-Judson G, Goetz MP, Soucy SM, Kolling F, Demidenko E, Miller TW
Clin Cancer Res. 2023 Aug 1;29(15):2767-2773. doi: 10.1158/1078-0432.CCR-23-0112.
PMID: 37260292

Pharmacological Induction of mesenchymal-epithelial transition chemosensitizes breast cancer cells and prevents metastatic progression.
Bagheri M, Aisha Mohamed G, Mohamed Saleem MA, Ognjenovic NB, Lu H, Kolling FW, Wilkins OM, Das S, La Croix IS, Nagaraj SH, Muller KE, Gerber SA, Miller TW, Pattabiraman DR
bioRxiv. 2023 Apr 21; pii: 2023.04.19.537586. doi: 10.1101/2023.04.19.537586. Epub 2023 Apr 21.
PMID: 37131809

The role of cancer cell bioenergetics in dormancy and drug resistance.
Tau S, Miller TW
Cancer Metastasis Rev. 2023 Mar;42(1):87-98. doi: 10.1007/s10555-023-10081-7. Epub 2023 Jan 25.
PMID: 36696004

Alpelisib Efficacy without Cherry-PI3King Mutations.
Tau S, Miller TW
Clin Cancer Res. 2023 Mar 14;29(6):989-990. doi: 10.1158/1078-0432.CCR-22-3411.
PMID: 36626159

Tumour, whole-blood, plasma and tissue concentrations of metformin in lung cancer patients.
Phillips JD, Pooler DB, Ness DB, Fay K, Tau S, Demidenko E, Hampsch RA, Lewis LD, Miller TW
Br J Clin Pharmacol. 2023 Mar;89(3):1027-1035. doi: 10.1111/bcp.15546. Epub 2022 Oct 12.
PMID: 36164710

High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer.
Traphagen NA, Hosford SR, Jiang A, Marotti JD, Brauer BL, Demidenko E, Miller TW
Oncogene. 2021 May;40(19):3408-3421. doi: 10.1038/s41388-021-01782-w. Epub 2021 Apr 19.
PMID: 33875787

Pan-Cancer Transcriptional Models Predicting Chemosensitivity in Human Tumors.
Wells JD, Griffin JR, Miller TW
Cancer Inform. 2021;20:11769351211002494. doi: 10.1177/11769351211002494. Epub 2021 Mar 19.
PMID: 33795931

Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.
Axelrod ML, Nixon MJ, Gonzalez-Ericsson PI, Bergman RE, Pilkinton MA, McDonnell WJ, Sanchez V, Opalenik SR, Loi S, Zhou J, Mackay S, Rexer BN, Abramson VG, Jansen VM, Mallal S, Donaldson J, Tolaney SM, Krop IE, Garrido-Castro AC, Marotti JD, Shee K, Miller TW, Sanders ME, Mayer IA, Salgado R, Balko JM
Clin Cancer Res. 2020 Nov 1;26(21):5668-5681. doi: 10.1158/1078-0432.CCR-19-3685. Epub 2020 Aug 21.
PMID: 32826327

View more publications on PubMed